Search
Results: 3
Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease
Sonali Wijetilleka, Chetan Mukhtyar, David Jayne, Aftab Ala, Philip Bright, Hector Chinoy, Lorraine Harper, Majid Kazmi, Sorena Kiani-Alikhan, Charles Li, Siraj Misbah, Louise Oni, Fiona Price-Kuehne, Alan Salama, Sarita Workman, David Wrench, Mohammed Yousuf Karim
Feb 24, 2020
BACKGROUND: Consensus guidelines are not available for the use of immunoglobulin replacement therapy (IGRT) in patients developing iatrogenic secondary antibody deficiency following B-cell targeted therapy (BCTT) in autoimmune...
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Joanna Tieu, Rona M Smith, Seerapani Gopaluni, Dinakantha S Kumararatne, Mark McClure, Ania Manson, Sally Houghton, David RW Jayne
Jun 07, 2021
OBJECTIVE: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement...
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
Joanna Tieu, Rona M. Smith, Seerapani Gopaluni, Dinakantha S. Kumararatne, Mark McClure, Ania Manson, Sally Houghton, David R. W. Jayne
May 26, 2021
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement...